Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vormetinib mesylate perioperative therapy in EGFR-mutant lung adenocarcinoma
ChiCTR2500105766Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of furmonertinib in Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoints: Progression-Free Survival (PFS), Major Pathological Response rate (MPR) and 1 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500105766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105766.